PROKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
PROKIDNEY CORP.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$1.40+0.06 (+4.89%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-18477.8%
Net margin
-7725.2%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +1075.0% | – | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 6.9% | |
| Return on assets | – | – | -17.8% | |
| Current ratio | – | – | 9.13 | |
| Interest coverage | – | – | -41251.8× | |
| Capex to revenue | – | – | 1701.7% |
Where the cash went
Fiscal 2021 to 2025, five years combined
Prokidney generated $463.93M from operations and spent $95.44M on capital expenditure, dividends and share buybacks. 90% of that went back into the business.
Generated
$463.93M
Used
$95.44M
Capital expenditure$85.94M90%Dividends$00%Share buybacks$9.50M10%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-7725.2%
×Asset turnover0.00×
×Equity multiplier-0.39×
=Return on equity, FY20256.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -7725.2% | 0.00× | -0.39× | 6.9% |
| FY2024 | -80507.9% | 0.00× | -0.41× | 5.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$68.99M
- Cash generatingOperating cash flow above zero-$120.12M
- Return on assets improvedROA up on the prior year-14.5% → -15.6%
- Earnings backed by cashOperating cash flow above net income-$120.12M vs -$68.99M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose10.93 → 9.13
- No dilutionShare count did not rise– → –
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00